November 2024, Vol 14, No 11
The ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification) provides a standardized avenue for classifying and recording diseases and medical conditions. Read More ›
By Maimah Karmo
Whether your patient is newly diagnosed or they are supporting a loved one through this journey, here are some essential pearls to offer as they begin navigating this challenging road. Read More ›
In this study, Sue S. Yom, MD, PhD, FASTRO, principal investigator of the trial and the Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in Head and Neck Cancer Radiation Oncology at the University of California, San Francisco, and her team tested 2 lower-intensity treatment regimens against a control arm of more standard chemoradiation for people with HPV-associated, locoregionally advanced oropharyngeal squamous cell carcinomas. Read More ›
The Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among Black men with early-stage disease, according to results presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington, DC. Read More ›
Data presented in 3 abstracts at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting, which took place in Washington, DC, last month support the safety and efficacy of a hyaluronic acid rectal spacer. Read More ›
Two recently published studies underscore the importance of cancer screening among incarcerated populations. Read More ›
Federal housing assistance may be associated with earlier-stage breast cancer, colorectal cancer, and non–small cell lung cancer diagnoses,... Read More ›
An analysis prepared by researchers at the American Cancer Society and presented at the 2024 American Society of Clinical Oncology Quality Care Symposium shows Medicaid expansion under the Affordable Care Act was associated with an increase in Medicaid enrollment among patients aged ≥65 years old were diagnosed with cancer. Read More ›
Officials with the FDA have approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib (Ibrance) and fulvestrant (Faslodex) for adults with endocrine-resistant,... Read More ›
Officials with the FDA have approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment,... Read More ›
Selpercatinib (Retevmo, Eli Lilly and Company) is now available for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation,... Read More ›